Comparison of Two Biphasic Insulin Aspart 30 Treatment Regimens in Subjects With Type 2 Diabetes Not Achieving HbA1c Treatment Targets on OADs Alone
Primary Purpose
Diabetes, Diabetes Mellitus, Type 2
Status
Completed
Phase
Phase 4
Locations
Iran, Islamic Republic of
Study Type
Interventional
Intervention
biphasic insulin aspart 30
biphasic insulin aspart 30
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes
Eligibility Criteria
Inclusion Criteria:
- Diagnosed with type 2 diabetes for a minimum of 6 months prior to Visit 1
- HbA1c at least 7.0 % - maximum 11 % at screening
- Subject is insulin naïve (short-term insulin treatment of up to 14 days is allowed)
- An antidiabetic regimen that has been stable for at least 3 months prior to screening
- An antidiabetic regimen that includes a minimum of 2 OADs
- OADs dosed at least 50% of the maximum recommended dose
Exclusion Criteria:
- Known or suspected hypersensitivity to trial product(s) or related products
- Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods (adequate contraceptive measures as required by local law or practice)
- The receipt of any investigational medicinal product within one month prior to this trial
- Suffer from a life threatening disease (cancer)
- Cardiac disease: class III or IV congestive heart failure (CHF), unstable angina, and or any myocardial infarction (treated or untreated) within 6 months prior to screening
- Hepatic insufficiency (Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) above 2 times the central laboratory's upper reference limit)
- Renal insufficiency (serum creatinine above 1.6 mg/dl for males; 1.4 mg/dl for females
- Recurrent hypoglycaemia or hypoglycaemic unawareness
- Anemia (haemoglobin below 10 mg/dl)
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Pre-breakfast BIAsp 30
Pre-dinner BIAsp 30
Arm Description
Outcomes
Primary Outcome Measures
Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 11
Estimated mean change from baseline in HbA1c after 11 weeks of treatment
Secondary Outcome Measures
Change in FPG (Fasting Plasma Glucose) From Baseline to Week 36
Estimated mean change from baseline in FPG after 36 weeks of treatment
Number of Treatment Emergent Hypoglycaemic Episodes
A hypoglycaemic episode will be defined as treatment emergent if the onset of the episode is on or after the first day of trial product, and no later than the last day on trial product.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01215435
Brief Title
Comparison of Two Biphasic Insulin Aspart 30 Treatment Regimens in Subjects With Type 2 Diabetes Not Achieving HbA1c Treatment Targets on OADs Alone
Official Title
An Open Labelled, Randomised, Parallel Trial; Efficacy and Safety Comparison of Two Different Biphasic Insulin Aspart 30 Treatment Initiation Regimens Followed by Intensification in Subjects With Type 2 Diabetes Mellitus Not Achieving Glycaemic Targets on OADs Alone in Iran
Study Type
Interventional
2. Study Status
Record Verification Date
October 2014
Overall Recruitment Status
Completed
Study Start Date
March 2011 (undefined)
Primary Completion Date
September 2012 (Actual)
Study Completion Date
September 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novo Nordisk A/S
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This trial is conducted in Asia. The aim of this trial is to compare the glycaemic control when subjects initiate a biphasic insulin aspart 30 treatment followed by an intensified treatment if treatment target of HbA1c below 7% is not reached by OAD (oral anti-diabetic drugs) alone.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes, Diabetes Mellitus, Type 2
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
245 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Pre-breakfast BIAsp 30
Arm Type
Experimental
Arm Title
Pre-dinner BIAsp 30
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
biphasic insulin aspart 30
Intervention Description
Administered subcutaneously (under the skin) once daily, before breakfast. The trial has 3 treatment phases for both treatment arms
Intervention Type
Drug
Intervention Name(s)
biphasic insulin aspart 30
Intervention Description
Administered subcutaneously (under the skin) once daily, before dinner. The trial has 3 treatment phases for both treatment arms
Primary Outcome Measure Information:
Title
Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 11
Description
Estimated mean change from baseline in HbA1c after 11 weeks of treatment
Time Frame
Week 0, Week 11
Secondary Outcome Measure Information:
Title
Change in FPG (Fasting Plasma Glucose) From Baseline to Week 36
Description
Estimated mean change from baseline in FPG after 36 weeks of treatment
Time Frame
Week 0, Week 36
Title
Number of Treatment Emergent Hypoglycaemic Episodes
Description
A hypoglycaemic episode will be defined as treatment emergent if the onset of the episode is on or after the first day of trial product, and no later than the last day on trial product.
Time Frame
Week 0 to Week 36
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosed with type 2 diabetes for a minimum of 6 months prior to Visit 1
HbA1c at least 7.0 % - maximum 11 % at screening
Subject is insulin naïve (short-term insulin treatment of up to 14 days is allowed)
An antidiabetic regimen that has been stable for at least 3 months prior to screening
An antidiabetic regimen that includes a minimum of 2 OADs
OADs dosed at least 50% of the maximum recommended dose
Exclusion Criteria:
Known or suspected hypersensitivity to trial product(s) or related products
Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods (adequate contraceptive measures as required by local law or practice)
The receipt of any investigational medicinal product within one month prior to this trial
Suffer from a life threatening disease (cancer)
Cardiac disease: class III or IV congestive heart failure (CHF), unstable angina, and or any myocardial infarction (treated or untreated) within 6 months prior to screening
Hepatic insufficiency (Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) above 2 times the central laboratory's upper reference limit)
Renal insufficiency (serum creatinine above 1.6 mg/dl for males; 1.4 mg/dl for females
Recurrent hypoglycaemia or hypoglycaemic unawareness
Anemia (haemoglobin below 10 mg/dl)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Global Clinical Registry (GCR, 1452)
Organizational Affiliation
Novo Nordisk A/S
Official's Role
Study Director
Facility Information:
City
Teheran
Country
Iran, Islamic Republic of
12. IPD Sharing Statement
Links:
URL
http://novonordisk-trials.com
Description
Clinical Trials at Novo Nordisk
Learn more about this trial
Comparison of Two Biphasic Insulin Aspart 30 Treatment Regimens in Subjects With Type 2 Diabetes Not Achieving HbA1c Treatment Targets on OADs Alone
We'll reach out to this number within 24 hrs